Advanced search
Publication Cover
OncoTargets and Therapy Volume 17, 2024 - Issue
Submit an article Journal homepage
19
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Impact of Combined Chemotherapy and Targeted Therapy on Pancreatic Neuroendocrine Carcinoma with Liver Metastasis: A Single-Center Modified Nomogram Analysis

Wenhao LuoDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-9914-5338View further author information
ORCID Icon,
Hao ChenDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaView further author information
&
Taiping ZhangDepartment of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 509-519 | Received 15 Apr 2024, Accepted 17 Jun 2024, Published online: 21 Jun 2024

References

  • Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–1342. doi:10.1001/jamaoncol.2017.0589
  • Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–154. doi:10.1007/s12022-022-09708-2
  • Garcia-Carbonero R, Sorbye H, Baudin E, et al. Vienna consensus conference participants, ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103(2):186–194. doi:10.1159/000443172
  • Zhang J, Zhu H, Shen L, et al. Baseline radiologic features as predictors of efficacy in patients with pancreatic neuroendocrine tumors with liver metastases receiving surufatinib. Chin J Cancer Res. 2023;35(5):526–535. doi:10.21147/j.issn.1000-9604.2023.05.09
  • National Health Commission of The People’s Republic of China. National guidelines for diagnosis and treatment of pancreatic cancer 2022 in China (English version). Chin J Cancer Res. 2022;34(3):238–255. doi:10.21147/j.issn.1000-9604.2022.03.05
  • Luo W, Zhang T. Primary tumor resection enhances the survival of pancreatic neuroendocrine carcinoma patients with liver metastasis under the definition of 2019 WHO classification. J Cancer Res Clin Oncol. 2023;149(11):9201–9212. doi:10.1007/s00432-023-04847-3
  • Garcia-Carbonero R, Anton-Pascual B, Modrego A, et al. Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward? Endocr Rev. 2023;44(4):724–736. doi:10.1210/endrev/bnad006
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Neuroendocrine and Adrenal Tumors Version 1.2023—August 2, 2023, NCCN Guidelines for Patients®; Available from: www.nccn.org/patients. Accessed June 18, 2024.
  • Rogowski W, Wachuła E, Gorzelak A, et al. Capecitabine and temozolomide combination for treatment of high-grade, well-differentiated neuroendocrine tumour and poorly-differentiated neuroendocrine carcinoma - retrospective analysis. Endokrynol Pol. 2019;70(4):313–317. doi:10.5603/EP.a2019.0010
  • Holmager P, Langer SW, Kjaer A, et al. Surgery in patients with gastro-entero-pancreatic neuroendocrine carcinomas, neuroendocrine tumors G3 and high grade mixed neuroendocrine-non-neuroendocrine neoplasms. Curr Treat Options Oncol. 2022;23(6):806–817. doi:10.1007/s11864-022-00969-x

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.